Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487559 | 0.80 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12CNR2 | |
| SCHEMBL13487573 | 0.77 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3543311 | 0.74 | MAPK14 (0.76) | MAPK14MAPK11MAPK13MAPK12MAPT | |
| SCHEMBL3551340 | 0.72 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3546397 | 0.71 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5242826 | 0.67 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12CNR2 | |
| SCHEMBL14459897 | 0.67 | MAPK14 (0.56) | MAPK14MAPK11MAPK13MAPK12CNR2 | |
| SCHEMBL16150798 | 0.67 | CNR1 (0.47) | MAPK14MAPK11MAPK13MAPK12CNR2 | |
| SCHEMBL669939 | 0.66 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL13791346 | 0.66 | MAPK14 (0.79) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885MAPK11 48/4885MAPK13 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.